Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
August 26, 2026
,
Shah, M. et al.
Clinical Cancer Research
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Next Generation Immune Checkpoint Inhibition with Botensilimab Plus Balstilimab in Recurrent Ovarian Cancer: Results by Platinum Sensitivity Status and 3-Year Overall Survival
Other Articles & Publications
International Gynecologic Cancer Society (IGCS)
October 3, 2026
,
Porter, R et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Phase 2 Trial of Botensilimab (Fc-Enhanced Anti–Ctla-4), Balstilimab (Anti–Pd-1) And Doxorubicin Delivered With Ultrasound/Microbubble-Based Blood-Brain Barrier Opening In Newly Diagnosed Mgmt Un-Methylated Glioblastoma: Initial Report
Other Articles & Publications
European Association of Neuro-Oncology
September 25, 2026
,
Sonabend, A et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Transcriptomic Profiling Identifies Immunotherapy-Responsive Phenotypes in Microsatellite-Stable Metastatic Colorectal Cancer
Other Articles & Publications
European Conference on Computational Biology
September 2, 2026
,
Konecny, T. et al.